Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)

Journal of the American Society of Nephrology

Volumn 7, Issue 12, 1996, Pages 2518-2526

  Kerjaschki, Dontscho ^a   Neale, Thomas James ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Heymann nephritis; Lipid peroxidation; Proteinuria

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN TYPE 4; COMPLEMENT MEMBRANE ATTACK COMPLEX; LIPOPROTEIN; MEMBRANE PROTEIN; OXIDOREDUCTASE; PROBUCOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

EXPERIMENTAL MODEL; GLOMERULUS CAPILLARY; HEYMANN NEPHRITIS; IMMUNE COMPLEX DEPOSITION; LIPID PEROXIDATION; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; REVIEW;

EID: 0030410436     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Schwartz MM. Membranous glomerulonephritis. In: Heptinstall RH, ed. Pathology of the Kidney. Boston: Little, Brown and Company; 1992:559-626.
2. Ponticelli C, Zucchelli P, Passerini P, et al.: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-1604.
3. Heymann W, Hackel DB, Harwood S, Wilson SGF, Hunter JLP: Production of the nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med 1959;100:660-664.
4. Sugisaki T, Klassen J, Andres GA, Milgrom F, McCluskey RT: Passive transfer of Heymann nephritis with serum. Kidney Int 1973;3:66-73.
5. Barabas AZ, Lannigan R: Induction of an autologous immune-complex glomerulonephritis in the rat by intravenous injection of heterologous anti-rat kidney tubular antibody. I. Production of chronic progressive immune-complex glomerulonephritis. Br J Exp Pathol 1974;55: 47-55.
6. Kerjaschki D. Molecular pathogenesis of membranous nephropathy [clinical conference]. Kidney Int 1992;41: 1090-1105.
7. Cavallo T: Membranous nephropathy. Insights from Heymann nephritis [comment]. Am J Pathol 1994;144: 651-658.
8. Farquhar MG, Saito A, Kerjaschki D, Orlando RA: The Heymann nephritis antigenic complex: Megalin (gp330) and RAP [editorial]. J Am Soc Nephrol 1995;6:35-47.
9. Farquhar MG: Molecular analysis of the pathologic autoimmune antigens of Heymann nephritis. Am J Pathol 1996;148:1331-1337.
10. Kerjaschki D, Farquhar MG: The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA 1982;79:5557-5581.
11. Saito A, Pietromonaco S, Loo AK, Farquhar MG: Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci USA 1994;91:9725-9729.
12. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK: Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. Embo J 1988;7:4119-4127.
13. Raychowdhury R, Niles JL, McCluskey RT, Smith JA: Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science 1989; 244:1163-1165.
14. Brown MS, Herz J, Kowal RC, Goldstein JL: The low-density lipoprotein-related protein: Double agent or decoy? Curr Opin Lipidology 1991;2:65-72.
15. 2-macroglobulin receptor. NY Acad Sci 1994;737:114-123.
16. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J: Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plastninogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 1992;267: 26172-26180.
17. Farquhar MG: The unfolding story of megalin (gp330): Now recognized as a drug receptor. J Clin Invest 1995; 96:1184.
18. Christensen EI, Gliemann J, Moestrup SK: Renal tubule gp330 is a calcium binding receptor for endocytic uptake of protein. J Histochem Cytochem 1992;40:1481-1490.
19. Krieger M, Herz J: Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994;63:601-637.
20. Kounnas MZ, Loukinova EB, Stefansson S, et al.: Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem 1995;270: 13070-13075.
21. Stefansson S, Chappell DA, Argraves KM, Strickland DK, Argraves WS: Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100. J Biol Chem 1995;270:19417-19421.
22. Kanalas JJ, Makker SP: Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. J Biol Chem 1991;266:10825-10829.
23. Moestrup SK, Christensen EI, Nielsen S, et al.: Binding and endocytosis of proteins mediated by epithelial gp330. Ann NY Acad Sci 1994;737:124-137.
24. Moestrup SK, Cui S, Vorum H, et al.: Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995;96:1404-1413.
25. Orlando RA, Exner M, Ullrich R, et al.: ApoE-bVLDL, aprotinin, and lactoferrin bind to the second ligand binding domain in megalin (gp330) [abstract]. Mol Biol Cell 1995;5:187.
26. Kerjaschki D, Farquhar MG: Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 1983;157:667-686.
27. Kerjaschki D, Miettinen A, Farquhar MG: Initial events in the formation of immune deposits in passive Heymann nephritis. gp330-anti-gp330 immune complexes form in epithelial coated pits and rapidly become attached to the glomerular basement membrane. J Exp Med 1987;166:109-128.
28. Pietromonaco S, Kerjaschki D, Binder S, Ullrich R, Farquhar MG: Molecular cloning of a cDNA encoding a major pathogenic domain of the Heymann nephritis antigen gp330. Proc Natl Acad Sci USA 1990;87:1811-1815.
29. 2-macroglobulin receptor. J Biol Chem 1991;266:21232-21238.
30. a2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen. J Biol Chem 1991;266:13364-13369.
31. Kerjaschki D, Ullrich R, Diem K, Pietromonaco S, Orlando RA, Farquhar MG: Identification of a pathogenic epitope involved in initiation of Heymann nephritis. Proc Natl Acad Sci USA 1992;89:11179-11183.
32. Huang J, Makker SP: Role of receptor-associated 39/45 kD protein in active Heymann nephritis. Kidney Int 1995;47:432-441.
33. Orlando RA, Farquhar MG: Functional domains of the receptor-associated protein (RAP). Proc Natl Acad Sci USA 1994;91:3161-3165.
34. Kerjaschki D, Ullrich R, Exner M, Orlando R, Farquhar MG: Induction of passive Heymann nephritis with antibodies specific for a synthetic peptide derived from the receptor associated protein. J Exp Med 1996;183:2007-2015.
35. Orlando RA, Kerjaschki D, Farquhar MG: Megalin (gp330) possesses an antigenic epitope capable of inducing passive Heymann nephritis independent of the nephritogenic epitope in receptor-associated protein. J Am Soc Nephrol 1995;6:61-67.
36. Saito A, Yamazaki H, Rader K, et al.: Mapping rat megalin: The second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation of immune deposits in Heymann nephritis. Proc Natl Acad Sci USA 1996;93:8601-8605.
37. Raychowdhury R, Zheng G, Brown D, McCluskey RT: Induction of Heymann nephritis with a gp330/Megalin fusion protein. Am J Pathol 1996;148:1613-1623.
38. Orlando RA, Kerjaschki D, Kurihara H, Biemesderfer D, Farquhar MG: gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc Natl Acad Sci USA 1992;89:6698-6702.
39. Farquhar MG, Kerjaschki D, Lundstrom M, Orlando RA: gp330 and RAP: The Heymann nephritis antigenic complex. Ann NY Acad Sci 1994;737:96-113.
40. Salant DJ, Belok S, Madaio MP, Couser WG: A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 1980;66:1339-1350.
41. Couser WG, Baker PJ, Adler S: Complement and the direct mediation of immune glomerular injury: A new perspective. Kidney Int 1985;28:879-890.
42. Kamata K, Baird LG, Erikson ME, Collins AB, McCluskey RT: Characterization of antigens and antibody specificities involved in Heymann nephritis. J Immunol 1985; 135:2400-2408.
43. Susani M, Schulze M, Exner M, Kerjaschki D: Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis [see comments]. Am J Pathol 1994;144:807-819.
44. Kerjaschki D, Schulze M, Binder S, et al.: Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol 1989;143:546-552.
45. Pruchno CJ, Burns MM, Schulze M, et al.: Urinary excretion of the C5b-9 membrane attack complex of complement is a marker of immune disease activity in autologous immune complex nephritis. Am J Pathol 1991;138:203-211.
46. Couser WG, Schulze M, Pruchno CJ: Role of C5b-9 in experimental membranous nephropathy. Nephrol Dial Transplant 1992;1:25-31.
47. Schulze M, Pruchno CJ, Burns M, Baker PJ, Johnson RJ, Couser WG: Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 1993;142:179-187.
48. Quigg RJ, Cybulsky AV, Jacobs JB, Salant DJ: Anti-Fx1A produces complement-dependent cytotoxicity of flomerular epithelial cells. Kidney Int 1988;34:43-52.
49. Salant DJ, Quigg RJ, Cybulsky AV: Heymann nephritis: Mechanisms of renal injury. Kidney Int 1989;35:976-984.
50. Kerjaschki D: Dysfunctions of cell biological mechanisms of visceral epithelial cell (podocytes) in glomerular diseases. Kidney Int 1994;45:300-313.
51. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH: Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase 9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 1996;4:1094-1101.
52. Floege J, Kriz W, Schulze M, et al.: Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 1995;96:2809-2819.
53. Neale TJ, Ullrich R, Ojha P, Poczewski H, Verhoeven AJ, Kerjaschki D: Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 1993;90:3645-3649.
54. Shah SV: Evidence suggesting a role for hydroxyl radical in passive Heymann's nephritis. Am J Physiol 1988;245: F337-F344.
55. Shah SV: Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 1989;36:1093-1106.
56. Adler S, Baker PJ, Johnson RJ, Ochi RF, Pritzl P, Couser WG: Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 1986;77:762-767.
57. Radeke HH, Cross AR, Hancock JT, et al.: Functional expression of NADPH oxidase components (alpha- and beta-subunits of cytochrome b558 and 45-kDa flavoprotein) by intrinsic human glomerular mesangial cells. J Biol Chem 1991;266:21025-21029.
58. Verhoeven AJ, Bolscher BG, Meerhof LJ, et al.: Characterization of two monoclonal antibodies against cytochrome b558 of human neutrophils. Blood 1989;73: 1686-1694.
59. Yang AH, Oberley TD, Oberley LW, Ramanathan R: Effect of cell substrate on antioxidant enzyme activities in cultured renal glomerular epithelium. Am J Pathol 1988;130:616-628.
60. Briggs RT, Drath DB, Karnovsky ML, Karnovsky MJ: Localization of NADH oxidase on the surface of human polymorphonuclear leukocytes by a new cytochemical technique. J Cell Biol 1975;67:566-586.
61. Palinski W, Rosenfeld ME, Yla-Herrtula G, et al.: Low density lipoproteins undergo oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1109-1116.
62. Witztum JL: Role of oxidized low density lipoprotein in atherogenesis. Br Heart J 1993;69:S12-S18.
63. Palinski W, Yla-Herttula S, Rosenfeld ME, et al.: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-335.
64. Neale TJ, Ojha PP, Exner M, et al.: Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J Clin Invest 1994;94:1577-1584.
65. Walton HA, Byrne J, Robinson GB: Studies of the permeation properties of glomerular basement membrane: Cross-linking renders glomerular basement membrane permeable to protein. Biochim Biophys Acta 1992;1138: 173-183.
66. Robinson GB, Walton HA: Glomerular basement membrane as a compressible ultrafilter. Microvasc Res 1989; 38:36-48.
67. Turner N, Mason PJ, Brown R, et al.: Molecular cloning of the human Goodpasture antigen demonstrates it to be the a3-chain of type IV collagen. J Clin Invest 1992;89: 592-601.
68. Hudson BG, Wieslander J, Wisdom BJ, Noelken M: Goodpasture syndrome: Molecular architecture and function of basement membrane antigen. Lab Invest 1989;61:256-269.
69. Kalluri R, Gattone VH, Noelken ME, Hudson BG: The a 3 chain of type IV collagen induces autoimmune Goodpasture syndrome. Proc Natl Acad Sci USA 1994;91: 6201-6205.
70. Kleppel MM, Kashtan CE, Butkowski RJ, Fish AJ, Michael AF: Alport familial nephritis: Absence of28 kDal noncollagenous monomers of type IV collagen in glomerular basement membrane. J Clin Invest 1987;80:263-271.
71. Fruebis J, Steinberg D, Dresel HA, Carew TE: A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 1994;19: 1994-2003.
72. Sasahara M, Raines EW, Chait A, et al.: Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994;94:155-164.
73. Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-795.
74. Itabe H, Takeshima E, Iwasaki H, et al.: A monoclonal antibody against oxidizes lipoproteins recognizes foam cells in atherosclerotic lesions: Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994;269:15272-15279.
75. Exner M, Susani M, Witztum JL, et al.: Lipoproteins accumulate in immune deposits and are modified by lipid peroxidation in passive Heymann nephritis. Am J Pathol 1996;149:1313-1320.
76. Grone HJ, Walli AK, Grone E, Kramer A, Clemens MR, Seidel D: Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells. Kidney Int 1990;37:1449-1459.
77. Kerjaschki D, Ojha PP, Susani M, et al.: A β 1-integrin receptor for fibronectin in human kidney glomeruli. Am J Pathol 1989;134:481-489.
78. Adler S: Integrin receptors in the glomerulus:potential role in glomerular injury. Am J Physiol 1992;262:F697-F704.